Department of Oral Implantology, Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, 56 Ling Yuan Xi Road, Guangzhou, 510006, Guangdong, People's Republic of China.
Guangdong Provincial Key Laboratory of Stomatology, 74 Zhong Shan Er Road, Guangzhou, 510006, Guangdong, People's Republic of China.
Sci Rep. 2021 Apr 14;11(1):8152. doi: 10.1038/s41598-021-87507-1.
Extra-short implants, of which clinical outcomes remain controversial, are becoming a potential option rather than long implants with bone augmentation in atrophic partially or totally edentulous jaws. The aim of this study was to compare the clinical outcomes and complications between extra-short implants (≤ 6 mm) and longer implants (≥ 8 mm), with and without bone augmentation procedures. Electronic (via PubMed, Web of Science, EMBASE, Cochrane Library) and manual searches were performed for articles published prior to November 2020. Only randomized controlled trials (RCTs) comparing extra-short implants and longer implants in the same study reporting survival rate with an observation period at least 1 year were selected. Data extraction and methodological quality (AMSTAR-2) was assessed by 2 authors independently. A quantitative meta-analysis was performed to compare the survival rate, marginal bone loss (MBL), biological and prosthesis complication rate. Risk of bias was assessed with the Cochrane risk of bias tool 2 and the quality of evidence was determined with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. 21 RCTs were included, among which two were prior registered and 14 adhered to the CONSORT statement. No significant difference was found in the survival rate between extra-short and longer implant at 1- and 3-years follow-up (RR: 1.002, CI 0.981 to 1.024, P = 0.856 at 1 year; RR: 0.996, CI 0.968 to 1.025, P = 0.772 at 3 years, moderate quality), while longer implants had significantly higher survival rate than extra-short implants (RR: 0.970, CI 0.944 to 0.997, P < 0.05) at 5 years. Interestingly, no significant difference was observed when bone augmentations were performed at 5 years (RR: 0.977, CI 0.945 to 1.010, P = 0.171 for reconstructed bone; RR: 0.955, CI 0.912 to 0.999, P < 0.05 for native bone). Both the MBL (from implant placement) (WMD: - 0.22, CI - 0.277 to - 0.164, P < 0.01, low quality) and biological complications rate (RR: 0.321, CI 0.243 to 0.422, P < 0.01, moderate quality) preferred extra-short implants. However, there was no significant difference in terms of MBL (from prosthesis restoration) (WMD: 0.016, CI - 0.036 to 0.068, P = 0.555, moderate quality) or prosthesis complications rate (RR: 1.308, CI 0.893 to 1.915, P = 0.168, moderate quality). The placement of extra-short implants could be an acceptable alternative to longer implants in atrophic posterior arch. Further high-quality RCTs with a long follow-up period are required to corroborate the present outcomes.Registration number The review protocol was registered with PROSPERO (CRD42020155342).
超短种植体(临床结果仍存在争议)在萎缩性部分或完全无牙颌中,正在成为一种潜在的选择,而不是使用骨增量的长种植体。本研究旨在比较超短种植体(≤6mm)和较长种植体(≥8mm)在不进行骨增量和进行骨增量的情况下的临床结果和并发症。通过电子检索(PubMed、Web of Science、EMBASE、Cochrane Library)和手动检索,检索了截至 2020 年 11 月之前发表的文章。仅选择了在同一研究中比较超短种植体和较长种植体,且报告了至少 1 年观察期的生存率的随机对照试验(RCT)。由 2 位作者独立进行数据提取和方法学质量(AMSTAR-2)评估。使用定量荟萃分析比较了超短种植体和较长种植体的生存率、边缘骨丧失(MBL)、生物学和修复体并发症发生率。使用 Cochrane 偏倚风险工具 2 和 Grading of Recommendations Assessment, Development, and Evaluation(GRADE)方法评估了偏倚风险,并确定了证据质量。共纳入 21 项 RCT,其中两项为预先注册,14 项符合 CONSORT 声明。在 1 年和 3 年的随访中,超短种植体和较长种植体的生存率没有显著差异(RR:1.002,CI 0.981 至 1.024,P=0.856;RR:0.996,CI 0.968 至 1.025,P=0.772,中质量),而较长种植体的生存率显著高于超短种植体(RR:0.970,CI 0.944 至 0.997,P<0.05)在 5 年时。有趣的是,在 5 年时进行骨增量时没有观察到显著差异(RR:0.977,CI 0.945 至 1.010,P=0.171 对于重建骨;RR:0.955,CI 0.912 至 0.999,P<0.05 对于原生骨)。MBL(从种植体放置开始)(WMD:-0.22,CI-0.277 至-0.164,P<0.01,低质量)和生物学并发症发生率(RR:0.321,CI 0.243 至 0.422,P<0.01,中质量)均倾向于超短种植体。然而,在 MBL(从修复体修复开始)(WMD:0.016,CI-0.036 至 0.068,P=0.555,中质量)或修复体并发症发生率(RR:1.308,CI 0.893 至 1.915,P=0.168,中质量)方面,两者之间没有显著差异。在萎缩性后弓中,超短种植体的放置可能是较长种植体的一种可接受的替代方案。需要进一步进行高质量、长期随访的 RCT 来证实目前的结果。注册号 本研究方案已在 PROSPERO(CRD42020155342)上注册。